title: HIV-1 resistance and trend analysis in newly diagnosed patients in Belgium.
abstract: A total of 1055 nucleotide sequences obtained from HIV patients diagnosed in 2008 and 2009 in Belgium were included in this prevalence study. The study population is a group of patients whose visit was considered by the clinician as the first contact with a Belgian AIDS reference centre or with another clinical centre experienced in HIV care. Prevalences of surveillance drug resistance mutations (SDRM) of 11·7% (47/394) and 11·0% (73/661) were observed in 2008 and 2009, respectively. The highest level of SDRM was observed towards nucleoside reverse transcriptase inhibitors (NRTIs) (7·8%), followed by the non-nucleoside reverse transcriptase inhibitors (NNRTIs) (4·2%) and Protease inhibitors (PIs) (2·3%). A potential clinical impact of the SDRM was demonstrated when using the current first-line therapy. A particularly high prevalence of SDRM was observed among intravenous drug users (IDUs) (29·4%). Reanalysis and comparing the data from previous Belgian studies using similar interpretation algorithms could not reveal a significant trend in SDRM prevalence over the last 5 years.
authors.forename: G
authors.initials: G
authors.lastname: Muyldermans
authors.forename: A
authors.initials: A
authors.lastname: Sasse
mesh_terms: D000328:Adult; D000465:Algorithms; D001530:Belgium / Q000453:epidemiology; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000187:drug effects; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D012307:Risk Factors
chemical_list: D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
keywords: Drug resistance mutations; HIV,; Surveillance,